EP4658094A1

EP4658094A1 - Agents, compositions, and methods for supporting motor development

Info

Publication number: EP4658094A1
Application number: EP24702564.6A
Authority: EP
Inventors: Purva RAJHANS; Nora Schneider; Jonas HAUSER
Original assignee: Societe des Produits Nestle SA; Nestle SA
Current assignee: Societe des Produits Nestle SA; Nestle SA
Priority date: 2023-01-31
Filing date: 2024-01-31
Publication date: 2025-12-10
Also published as: CN120569137A; AU2024214972A1; WO2024160873A1; JP2026502662A; MX2025008574A

Abstract

The present invention relates to one or more human milk oligosaccharides (HMOs) for use in supporting motor development in a subject, wherein the one or more HMOs comprise or consist of: 3' sialyllactose (3'-SL), lacto-N-hexaose (LNH), and/or disyallacto-N-tetraose (DSLNT).

Description

AGENTS, COMPOSITIONS, AND METHODS FOR SUPPORTING MOTOR DEVELOPMENT FIELD OF THE INVENTION The present invention relates to agents, compositions and methods for supporting motor development. BACKGROUND TO THE INVENTION Infancy is a critical period during which the brain undergoes significant maturation which is linked with development of certain behaviours and cognitive outcomes. Effective development of motor skills is a crucial aspect of a child’s development (see e.g. Adolph K.E., Hoch J.E., 2020. Nestlé Nutr Inst Workshop Se.95, pp136-144). The evidence linking breastfeeding with early motor development has been mixed, with some studies showing improved motor development in breastfed infants and toddlers but other studies showing no associations or, specifically, no improvement in gross motor development. The relation between breastfeeding and the attainment of motor skills is difficult to characterise because of problems that are common in studies, such as incomplete control for confounding variables, retrospective exposure assessment, varying assessment of motor skills across studies, and even the assessment of some motor skills too early (see Michels, K.A., et al., 2017. The American Journal of Clinical Nutrition, 106(6), pp.1456-1462). Thus, there is a demand for new nutritional interventions to promote motor development, for example in infants, toddlers or young infants. There is a need to deliver such benefit in a manner that does not induce side effects and/or in a manner that is easy to deliver, and well accepted by the parents or health care practitioners. There is also a need to deliver such benefits in a manner that keeps the cost of such delivery reasonable and affordable by most. SUMMARY OF THE INVENTION The present inventors have surprisingly found that specific human milk oligosaccharides (HMOs) are associated with positive motor skills in human milk-fed infants. The HMOs identified by the inventors have not previously been reported to be associated with motor skills. In one aspect, the present invention provides one or more human milk oligosaccharides (HMOs) for use in supporting motor development in a subject, wherein the one or more HMOs comprise or consist of: 3’ sialyllactose (3’-SL), lacto-N-hexaose (LNH), and/or disyallacto-N- tetraose (DSLNT). In another aspect, the present invention provides use of one or more human milk oligosaccharides (HMOs) for supporting motor development in a subject, wherein the one or more HMOs comprise or consist of: 3’ sialyllactose (3’-SL), lacto-N-hexaose (LNH), and/or disyallacto-N-tetraose (DSLNT). In another aspect, the present invention provides a method for supporting motor development in a subject, comprising administering to the subject one or more human milk oligosaccharides (HMOs), wherein the one or more HMOs comprise or consist of: 3’ sialyllactose (3’-SL), lacto- N-hexaose (LNH), and/or disyallacto-N-tetraose (DSLNT). Any suitable HMOs described herein may be used. In some embodiments, the one or more HMOs comprise or consist of 3’-SL. In some embodiments, the one or more HMOs comprise or consist of LNH. In some embodiments, the one or more HMOs comprise or consist of DSLNT. The one or more HMOs may be administered by any suitable means and in any suitable amounts. Suitably, the one or more HMOs are administered by oral administration. Suitably, the one or more HMOs are administered separately, simultaneously or sequentially. In preferred embodiments, the one or more HMOs are administered simultaneously. Suitably, the one or more HMOs are administered to the subject in a total amount of from about 0.05 g/day to about 5 g/day. Suitably, 3’-SL is administered to the subject in an amount of from about 0.05 g/day to about 5 g/day. Suitably, LNH is administered to the subject in an amount of from about 0.05 g/day to about 5 g/day. Suitably, DSLNT is administered to the subject in an amount of from about 0.1 g/day to about 5 g/day. The one or more HMOs may be provided in any suitable form. Suitably, the one or more HMOs are in the form of a nutritional composition. In some embodiments, the nutritional composition is an infant formula, a follow-on formula, or a growing-up milk. In preferred embodiments, the nutritional composition is an infant formula. Suitably, the starter infant formula, follow-on formula, and growing-up milk each comprise from about 60 kcal/100mL to about 80 kcal/100mL, protein in an amount of from about 1.5 g/100kcal to about 2.5 g/100kcal, carbohydrate in an amount of from about 8 g/100kcal to about 15 g/100kcal, and lipids in an amount of from about 3 g/100kcal to about 8 g/100kcal. The nutritional composition may comprise the one or more HMOs in any suitable amount. Suitably, the nutritional composition comprises the one or more HMOs in a total amount of from about 0.05 g/L to about 5 g/L. Suitably, the nutritional composition comprises 3’-SL in an amount of from about 0.05 g/L to about 1.0 g/L. Suitably, the nutritional composition comprises LNH in an amount of from about 0.05 g/L to about 1.0 g/L. Suitably, the nutritional composition comprises DSLNT in an amount of from about 0.1 g/L to about 2.0 g/L. The subject may be any suitable subject. The subject may be a human subject. In some embodiments, the subject is an infant, a toddler or a young child. In preferred embodiments, the subject is an infant. In some embodiments, the subject is aged about 12 months or younger. In some embodiments, the subject is aged about 11 months or younger, about 10 months or younger, about 9 months or younger, about 8 months or younger, about 7 months or younger, or about 6 months or younger. The one or more HMOs may promote the development of the subject’s fine motor skills and/or gross motor skills. The one or more HMOs may improve the subject’s motor skills. The one or more HMOs may improve the ability of the subject to control and coordinate muscles to make desired movements. The subject’s motor skills may be determined using a Bayley scale, such as Bayley-III. DESCRIPTION OF DRAWINGS Figure 1 – Association of 3’-SL in breast milk at 3 months with fine motor scores in infants at 12 months Regression model approach was used to determine association between 3’-SL in breast milk collected at 2 and 3 months and fine motor scores as determined using a Bayley-III scale at 12 months, p=0.0256. Figure 2 – Association of LNH in breast milk at 3 months with overall motor scores in infants at 6 months Regression model approach was used to determine association between LNH in breast milk collected at 3 months and overall motor scores as determined using a Bayley-III scale at 6 months, p=0.0116. Figure 3 – Association of DSLNT in breast milk at 2 months with overall motor scores in infants at 6 months Regression model approach was used to determine association between DSLNT in breast milk collected at 2 months, and overall motor scores as determined using a Bayley-III scale at 6 months, p=0.027. DETAILED DESCRIPTION Various preferred features and embodiments of the present invention will now be described by way of non-limiting examples. The skilled person will understand that they can combine all features of the invention disclosed herein without departing from the scope of the invention as disclosed. Any reference to prior art documents in this specification is not to be considered an admission that such prior art is widely known or forms part of the common general knowledge in the field. All publications mentioned in the specification are herein incorporated by reference. As used in this specification, the words “comprises”, “comprising”, and similar words, are not to be interpreted in an exclusive or exhaustive sense. In other words, they are intended to mean “including, but not limited to“. The terms “comprises”, “comprising”, and similar words also include the term “consisting of“. The practice of the present invention will employ, unless otherwise indicated, conventional techniques which are within the capabilities of one of ordinary skill in the art. Such techniques are explained in the literature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Numeric ranges are inclusive of the numbers defining the range and all percentages disclosed herein are on a w/w basis, unless stated otherwise. As used herein the term “about” means approximately, in the region of, roughly, or around. When the term “about” is used in conjunction with a numerical value or range, it modifies that value or range by extending the boundaries above and below the numerical value(s) set forth. In general, the terms “about” and “approximately” are used herein to modify a numerical value(s) above and below the stated value(s) by 10%. Human milk oligosaccharides (HMOs) The present invention relates to the use one or more human milk oligosaccharides (HMOs) to promote motor development and/or improve motor skills. In some embodiments, the one or more HMOs are used in a therapeutic method. The one or more HMOs may be administered by any suitable route and in any suitable form. Suitably, the one or more HMOs are administered by oral and/or enteral administration. In preferred embodiments, the one or more HMOs are administered by oral administration. The one or more HMOs may be administered separately, simultaneously or sequentially. In preferred embodiments, the one or more HMOs are administered simultaneously. Many different kinds of HMOs are found in human milk and are typically based on a combination of glucose, galactose, sialic acid (N-acetylneuraminic acid), fucose and/or N- acetylglucosamine with many and varied linkages between them. Almost all HMOs have a lactose moiety at their reducing end while sialic acid and/or fucose (when present) occupy terminal positions at the non-reducing ends. HMOs can be acidic (e.g. charged sialic acid containing oligosaccharides) or neutral (e.g. fucosylated oligosaccharides). See e.g. Chen, X., 2015. Advances in carbohydrate chemistry and biochemistry, 72, pp.113-190. HMOs found in human milk include Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), 2′- Fucosyllactose (2’FL), 3-Fucosyllactose (3FL), Lactodifucotetraose (LDFT), Lacto-N- difucohexaose I (LNDFHI), Lacto-N-fucopentaose I (LNFP-I), Lacto-N-fucopentaose II (LNFP- II), Lacto-N-fucopentaose III (LNFP-III), Trifucosyllacto-N-hexaose (TF-LNH), 3′-Sialyllactose (3’SL), 6′-Sialyllactose (6’SL), Disialyllacto-N-tetraose (DSLNT), Sialyllacto-N-neotetraose c (LST c) and Fucosyldisialyllacto-N-hexaose I (FDS-LNH-I). See e.g. Soyyılmaz, B., et al., 2021. Nutrients, 13(8), p.2737. In some embodiments, the one or more HMOs comprise or consist of: 3’ sialyllactose (3’-SL), lacto-N-hexaose (LNH), and/or disyallacto-N-tetraose (DSLNT). In some embodiments, the one or more HMOs comprise or consist of: 3’ sialyllactose (3’-SL), lacto-N-hexaose (LNH), or disyallacto-N-tetraose (DSLNT). The subject may be administered any suitable amounts of the one or more HMOs, in any suitable form and via any suitable route of administration (e.g. in any form and via any route described herein). Suitable doses of HMOs are described in e.g. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), 2022. EFSA Journal, 20(12), p.e07645. Suitably, the one or more HMOs are administered to the subject in a total amount of at least about 0.05 g/day, at least about 0.1 g/day, at least about 0.2 g/day, at least about 0.3 g/day, at least about 0.4 g/day, or at least about 0.5 g/day. Suitably, the one or more HMOs are administered to the subject in an amount of about 5 g/day or less, about 4 g/day or less, about 3 g/day or less, about 2 g/day or less, or about 1 g/day or less. Suitably, the one or more HMOs are administered to the subject in an amount of from about 0.05 g/day to about 5 g/day, from about 0.1 g/day to about 2 g/day or from about 0.1 g/day to about 1 g/day. The HMOs may be obtained by any suitable method. Suitable methods for synthesising HMOs will be well known to those of skill in the art. For example, processes have been developed for producing oligosaccharides by microbial fermentations, enzymatic processes, chemical syntheses, or combinations of these technologies (see e.g. Zeuner et al., 2019. Molecules, 24(11), p.2033). 3’ sialyllactose (3’-SL) In some embodiments, the one or more HMOs comprise or consist of 3’ sialyllactose (3’-SL). In some embodiments, the one or more HMOs consist of 3’-SL. In some embodiments, the one or more HMOs are 3’-SL. 3’ sialyllactose (3’-SL) is an abundant sialylated HMO in human milk that may have the following structure: Where: is N-acetylneuraminic acid, is galactose, and is glucose. Suitably, 3’-SL is administered to the subject in an amount of at least about 0.05 g/day, at least about 0.1 g/day, or at least about 0.2 g/day. Suitably, 3’-SL is administered to the subject in an amount of about 5 g/day or less, about 1 g/day or less, or about 0.5 g/day or less. Suitably, 3’-SL is administered to the subject in an amount of from about 0.05 g/day to about 5 g/day, from about 0.05 g/day to about 1 g/day, or from about 0.05 g/day to about 0.5 g/day. Lacto-N-hexaose (LNH) In some embodiments, the one or more HMOs comprise or consist of lacto-N-hexaose (LNH). In some embodiments, the one or more HMOs consist of LNH. In some embodiments, the one or more HMOs are LNH. Lacto-N-hexaose (LNH) is a non-fucosylated, non-sialylated Galβ1-3GlcNAc core (human milk oligosaccharide that may have the following structure: Where: is galactose, is N-acetylglucosamine, and is glucose. Suitably, LNH is administered to the subject in an amount of at least about 0.05 g/day, at least about 0.1 g/day, or at least about 0.2 g/day. Suitably LNH is administered to the subject in an amount of about 5 g/day or less, about 1 g/day or less, or about 0.5 g/day or less. Suitably, LNH is administered to the subject in an amount of from about 0.05 g/day to about 5 g/day, from about 0.05 g/day to about 1 g/day, or from about 0.05 g/day to about 0.5 g/day. Disyallacto-N-tetraose (DSLNT) In some embodiments, the one or more HMOs comprise or consist of disyallacto-N-tetraose (DSLNT). In some embodiments, the one or more HMOs consist of DSLNT. In some embodiments, the one or more HMOs are DSLNT. Disyallacto-N-tetraose (DSLNT) is a di-sialylated Galβ1-3GlcNAc core human milk oligosaccharide that may have the following structure: Where: N-acetylneuraminic acid, is galactose, is N- acetylglucosamine, and is glucose. Suitably, DSLNT is administered to the subject in an amount of at least about 0.1 g/day, at least about 0.15 g/day, or at least about 0.2 g/day. Suitably, DSLNT is administered to the subject in an amount of about 5 g/day or less, about 1 g/day or less, or about 0.5 g/day or less. Suitably, DSLNT is administered to the subject in an amount of from about 0.1 g/day to about 5 g/day, from about 0.1 g/day to about 1 g/day, or from about 0.1 g/day to about 0.5 g/day. Nutritional compositions Suitably, the one or more HMOs are in the form of a composition. The composition may comprise the one or more HMOs in any effective amount. In one aspect, the present invention provides a composition (e.g. a nutritional composition such as an infant formula, a follow-on formula, or a growing-up milk) comprising one or more human milk oligosaccharides (HMOs) for use in supporting motor development and/or improving motor skills. In another aspect, the present invention provides use of one or more human milk oligosaccharides (HMOs) for the manufacture of a composition (e.g. a nutritional composition such as an infant formula, a follow-on formula, or a growing-up milk) for supporting motor development and/or improving motor skills. In another aspect, the present invention provides a method for supporting motor development and/or improving motor skills, wherein the method comprises administering a composition (e.g. a nutritional composition such as an infant formula, a follow-on formula, or a growing-up milk) comprising one or more human milk oligosaccharides (HMOs). The composition can be any type of composition in which the one or more HMOs can be incorporated, such as a composition in the form of a food or beverage product, a nutritional supplement, or a pharmaceutical composition. The composition may be in solid (e.g. powder), liquid or semi-liquid form. The one or more HMOs may be in the form of a food composition, a beverage, a nutritional formula, a nutritional supplement, a nutraceutical, or a pharmaceutical composition. Food and beverage products include all products intended to be consumed orally by human beings, for the purpose of providing nutrition and/or pleasure. For example, the composition may be a food or beverage product, such as for infants, toddlers and/or young children. Examples of food and beverage products include dairy products such as milk products or yogurts, soups, sauces, sweet and savoury snacks, powdered drinks and cereal products. In some embodiments, the one or more HMOs are in the form of a nutritional composition, a medical food product for clinical nutrition, or a supplement. In some embodiments, the one or more HMOs are in the form of a nutritional composition. As used herein, a “nutritional composition” may mean a composition which nourishes a subject. This nutritional composition is usually to be taken orally or intravenously, and typically includes a lipid or fat source and a protein source. The nutritional composition may be a synthetic nutritional composition. As used herein, a “synthetic nutritional composition” may mean a nutritional composition obtained by chemical and/or biological means that can be chemically substantially identical to a naturally composition. In some embodiments, the one or more HMOs are in the form of a medical food product for clinical nutrition. As used herein, a “medical food product for clinical nutrition” may also be known as a “Food for Special Medical Purposes (FSMP)” and refer to specialised foods designed to help meet the nutritional or dietary needs of subjects living with a disease, disorder or medical condition who are temporarily or permanently unable to achieve an adequate nutritional intake from normal foods or through modification of the normal diet. In some embodiments, the one or more HMOs are in the form of an infant formula, a follow- on formula, or a growing-up milk. In some embodiments, the one or more HMOs are in the form of an infant formula. The term "infant formula" as used herein may refer to a foodstuff intended for particular nutritional use by infants during the first months of life and satisfying by itself the nutritional requirements of this category of person (see e.g. Article 2(c) of the European Commission Directive 91/321/EEC 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae). It also refers to a nutritional composition intended for infants and as defined in Codex Alimentarius (Codex STAN 72-1981) and Infant Specialities (incl. Food for Special Medical Purpose). The infant formula can be a preterm infant formula, a human milk fortifier, a starter infant formula, a follow-on formula, a baby-food formula, or an infant cereal formula. In some embodiments, the one or more HMOs are in the form of a starter infant formula. Typically, a “starter infant formula” is intended for infants from birth as a breast-milk substitute. In some embodiments, the one or more HMOs are in the form of follow-on formula. A “follow- up formula” or “follow-on formula” may be given from the 6th month onwards. It may constitute the principal liquid element in the progressively diversified diet of this category of person. In some embodiments, the one or more HMOs are in the form of a preterm infant formula. The term "preterm infant formula" as used herein means an infant formula intended for a preterm infant. In some embodiments, the one or more HMOs are in the form of a milk fortifier. The term "milk fortifier" as used herein refers to liquid or solid nutritional compositions suitable for mixing with breast milk (which is human milk for a human milk fortifier) or infant formula. It is used to increase the calories, protein, minerals and vitamins in breast milk fed to preterm infants or infants with a low birth weight. The term “breast milk” is to be understood as the mother’s milk or the colostrum of the mother or a donor’s milk or the colostrum of a donor’s milk. In some embodiments, the one or more HMOs are in the form of a baby-food formula. The term "baby food formula" as used herein means a foodstuff intended for particular nutritional use by infants or children such as young children, during the first years of life. In some embodiments, the one or more HMOs are in the form of a growing-up milk. The term “growing-up milk” (or GUM) as used herein refers to a milk formula product given from one year onwards. It is generally a dairy-based beverage adapted for the specific nutritional needs of young children (e.g. children aged from about 1 to about 3). Growing-up milk may also be known as “young-child formula” or “toddlers’ milk”. In some embodiments, the one or more HMOs are in the form of an infant cereal composition. The term “infant cereal composition” as used herein refers to a foodstuff intended for particular nutritional use by infants or children such as young children, during the first years of life. In some embodiments, the one or more HMOs are in the form of a milk formula. The term "milk formula" as used herein may refer to a foodstuff intended for e.g. childhood nutrition, which may provide the sole source or supplemental nutrition for children e.g. aged about 3 years or older. In some embodiments, the milk formula is a grow milk. In some embodiments, the composition is in a powder form and reconstituted in an aqueous medium (e.g. water) prior to administration. In other embodiments, the composition is in a liquid form ready for administration (e.g. a ready-to-feed formula). In another embodiment, the one or more HMOs are in the form of a supplement. As used herein, a "supplement" or “dietary supplement” may be used to complement the nutrition of a subject (it is typically used as such but it might also be added to any kind of compositions intended to be ingested by the subject). When the composition is a supplement, it can be provided in the form of unit doses. Supplements are typically present in the form of a liquid, a gel, a powder or a tablet or capsule. Powder supplements typically encompass supplements to be dissolved in water or milk, or to be sprinkled on food or in a beverage. Such supplements are intended to provide additional nutrients and/or a health benefit to the subject consuming it. A supplement can be used for providing nutrients and/or a health benefit to human beings, as well as to animals. In another embodiment, the one or more HMOs are in the form of a fortifier. The fortifier can be an infant formula fortifier or growing-up milk fortifier. In another embodiment, the one or more HMOs are in the form of a pharmaceutical product. Pharmaceutical products include for example drops, syrups, powder, tablet or capsule products intended to treat or prevent an adverse medical condition in a subject in need thereof. Human milk oligosaccharides (HMOs) The one or more HMOs may be present in the composition in any suitable amounts. For example, in an infant formula, follow-on formula, or growing-up milk, the skilled person may base the amount of an HMO on the amounts found in human breast milk produced for an infant or child of the same age, in particular by a nutritionally replete mother (see e.g. Soyyılmaz, B., et al., 2021. Nutrients, 13(8), p.2737). Such amounts may fall within the following ranges in human breast milk: 3’-SL: about 0.05 g/L to about 0.5 g/L; LNH: about 0.05 g/L to about 0.5 g/L; and DSLNT: about 0.05 g/L to about 1.0 g/L. However, they may be outside depending on for example bioavailability of said HMOs from infant formula in comparison to human breastmilk. Suitably, the nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) comprises the one or more HMOs in a total amount of at least about 0.05 g/L, at least about 0.075 g/L, or at least about 0.1 g/L. Suitably, the nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) comprises the one or more HMOs in a total amount of about 10.0 g/L or less, about 5.0 g/L or less or about 2.5 g/L or less. Suitably, the nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) comprises the one or more HMOs in a total amount of from about 0.05 g/L to about 10.0 g/L, from about 0.05 g/L to about 5.0 g/L, about 0.075 g/L to about 5.0 g/L, or about 0.1 g/L to about 2.5 g/L. If the nutritional composition is in the form of a powder these amounts may be following reconstitution with liquid according to the instructions provided. Suitably, the nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) comprises the one or more HMOs in a total amount of at least about 0.05 wt%, at least about 0.1 wt%, or at least about 0.2 wt%, on a dry weight basis. Suitably, the nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) comprises the one or more HMOs in a total amount of about 5 wt% or less, about 2 wt% or less or about 1 wt% or less, on a dry weight basis. Suitably, the nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) comprises the one or more HMOs in a total amount of from about 0.05 wt% to about 5 wt%, about 0.1 wt% to about 2 wt%, or about 0.1 wt% to about 1 wt%, on a dry weight basis. Suitably, the nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) comprises 3’-SL in an amount of at least about 0.01 g/L, at least about 0.02 g/L, or at least about 0.05 g/L. Suitably, the nutritional composition comprises 3’-SL in an amount of about 1.0 g/L or less, about 0.8 g/L or less, or about 0.5 g/L or less. Suitably, the nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) comprises 3’-SL in an amount of from about 0.01 g/L to about 1.0 g/L, from about 0.02 g/L to about 0.8 g/L, or from about 0.05 g/L to about 0.5 g/L. If the nutritional composition is in the form of a powder these amounts may be following reconstitution with liquid according to the instructions provided. Suitably, the nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) comprises LNH in an amount of at least about 0.01 g/L, at least about 0.02 g/L, or at least about 0.05 g/L. Suitably, the nutritional composition comprises LNH in an amount of about 1.0 g/L or less, about 0.8 g/L or less, or about 0.5 g/L or less. Suitably, the nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) comprises LNH in an amount of from about 0.01 g/L to about 1.0 g/L, from about 0.02 g/L to about 0.8 g/L, or from about 0.05 g/L to about 0.5 g/L. If the nutritional composition is in the form of a powder these amounts may be following reconstitution with liquid according to the instructions provided. Suitably, the nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) comprises DSLNT in an amount of at least about 0.01 g/L, at least about 0.02 g/L, at least about 0.05 g/L, or at least about 0.1 g/L. Suitably, the nutritional composition comprises DSLNT in an amount of about 2.0 g/L or less, about 1.5 g/L or less, or about 1.0 g/L or less. Suitably, the nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) comprises DSLNT in an amount of from about 0.02 g/L to about 2.0 g/L, from about 0.05 g/L to about 1.5 g/L, or from about 0.1 g/L to about 1.0 g/L. If the nutritional composition is in the form of a powder these amounts may be following reconstitution with liquid according to the instructions provided. Other components A nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) of the invention may contain a protein source, a carbohydrate source and a lipid source. In some embodiments however, especially if a nutritional composition of the invention is a supplement or a fortifier, there may be only lipids (or a lipid source). The nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) of the invention may comprise from about 50 kcal/100mL to about 90 kcal/100ml, from about 55 kcal/100mL to about 85 kcal/100ml, from about 60 kcal/100mL to about 80 kcal/100ml, from about 65 kcal/100mL to about 75 kcal/100ml, or from about 65 kcal/100mL to about 70 kcal/100ml. If the nutritional composition is in the form of a powder these amounts may be following reconstitution with liquid according to the instructions provided. The nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) of the invention may comprise about 100 kcal/100g to about 1000 kcal/100g, about 200 kcal/100g to about 800 kcal/100g, or about 400 kcal/100g to about 600 kcal/100g, on a dry weight basis. Protein A nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) according to the invention may contain a protein source. The protein may be in an amount of from about 1g to about 4g per 100 kcal, about 1.5g to about 3g per 100 kcal, or about 1.5g to about 2.5g per 100 kcal. Protein sources based on, for example, whey, casein and mixtures thereof may be used as well as plant based protein sources, for example, based on soy. As far as whey proteins are concerned, the protein source may be based on acid whey or sweet whey or mixtures thereof and may include alpha-lactalbumin and beta-lactoglobulin in any desired proportions. In some embodiments the protein source is whey predominant (i.e. more than 50% of proteins are coming from whey proteins, such as more than 60% or more than 70%). The proteins may be intact or hydrolysed or a mixture of intact and hydrolysed proteins. By the term "intact" it is meant that the main part of the proteins are intact, i.e. the molecular structure is not altered, for example at least 80% of the proteins are not altered, such as at least 85% of the proteins are not altered, preferably at least 90% of the proteins are not altered, even more preferably at least 95% of the proteins are not altered, such as at least 98% of the proteins are not altered. In a particular embodiment, 100% of the proteins are not altered. The term "hydrolysed" means in the context of the present invention a protein which has been hydrolysed or broken down into its component amino acids. The proteins may be either fully or partially hydrolysed. If hydrolysed proteins are required, the hydrolysis process may be carried out as desired and as is known in the art. For example, whey protein hydrolysates may be prepared by enzymatically hydrolysing the whey fraction in one or more steps. If the whey fraction used as the starting material is substantially lactose free, it is found that the protein suffers much less lysine blockage during the hydrolysis process. This enables the extent of lysine blockage to be reduced from about 15% by weight of total lysine to less than about 10% by weight of lysine; for example about 7% by weight of lysine which greatly improves the nutritional quality of the protein source. In one particular embodiment, the proteins of the composition are hydrolysed, fully hydrolysed or partially hydrolysed. The degree of hydrolysis (DH) of the protein can be between 2 and 20, or between 8 and 40, or between 20 and 60 or between 20 and 80 or more than 10, 20, 40, 60, 80 or 90. At least 70%, 80%, 85%, 90%, 95% or 97% of the proteins may be hydrolysed. In a particular embodiment, 100% of the proteins are hydrolysed. In one particular embodiment, the proteins of the composition are plant based protein. Carbohydrate A nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) according to the present invention may contain a carbohydrate source. The carbohydrate may be in an amount of from about 5g to about 20g per 100 kcal, about 10g to about 15g per 100 kcal, about 8g to about 15g per 100 kcal. Any carbohydrate source conventionally found in nutritional compositions such as lactose, sucrose, saccharose, maltodextrin, starch and mixtures thereof may be used although one of the preferred sources of carbohydrates is lactose. Lipid A nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) according to the present invention may contain lipids and essential fatty acids. The lipids may be in an amount of from about 1g to about 10g per 100 kcal, about 2g to about 8g per 100 kcal, or about 3g to about 8g per 100 kcal. Non-limiting examples of lipids include: palm olein, high oleic sunflower oil, high oleic safflower oil, canola oil, fish oil, coconut oil, bovine milk fat, and combinations thereof. It may be particularly beneficial if the composition comprises fat in an amount of about 25 to about 30g/100g dry weight of the composition. Non-limiting examples of essential fatty acids include: linoleic acid (LA), α-linolenic acid (ALA). Compositions of the invention may further contain gangliosides monosialoganglioside-3 (GM3) and disialogangliosides 3 (GD3), and combinations thereof. Others A nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) of the invention may also contain all vitamins and minerals understood to be essential in the daily diet and in nutritionally significant amounts. Minimum requirements have been established for certain vitamins and minerals. Examples of minerals, vitamins and other nutrients optionally present in the composition of the invention include vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin E, vitamin K1, vitamin K2, vitamin C, vitamin D, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chlorine, potassium, sodium, selenium, chromium, molybdenum, taurine, and L-carnitine. Minerals are usually added in salt form. The presence and amounts of specific minerals and other vitamins will vary depending on the intended population. If necessary, a nutritional composition (e.g. infant formula, follow-on formula, or growing-up milk) of the invention may contain emulsifiers and stabilisers such as soy, lecithin, citric acid esters of mono- and diglycerides, and the like. Preparation of compositions The compositions according to the present invention may be prepared by any known or otherwise suitable manner. For example, a nutritional composition (e.g. infant formula, follow- on formula, or growing-up milk) may be proposed by blending together a source of protein with a carbohydrate source and a lipid source in appropriate proportions. If used, emulsifiers may be included at this stage. Vitamins and minerals may be added at this stage, but may also be added later to avoid thermal degradation. Water, preferably water which has been subjected to reverse osmosis or deionized water, may then be added and mixed in to form a liquid mixture. The temperature of mixing is preferably room temperature, but may also be higher. The liquid mixture may then be thermally treated to reduce bacterial loads. The mixture may then be homogenized. If it is desired to produce a powdered composition, the homogenized mixture is dried in a suitable drying apparatus, such as a spray drier or freeze drier and converted into powder. Processes used in the manufacture of formula are based on the concept that the products must be nutritionally adequate and microbiologically safe to consume. Thus, steps that eliminate or restrict microbiological growth are central to production processes. The processing technology for each specific formula is proprietary to the manufacturer but, in general, it involves the preservation of an oil-in-water (o/w) emulsion by dehydration in the case of powder products or, sterilization in the case of ready-to-feed or concentrated liquid products. Powdered formula may be produced using various processes, such as dry blending dehydrated ingredients to constitute a uniform formula or hydrating and wet-mixing a mixture of macro-ingredients, such as fat, protein and carbohydrate ingredients and then evaporating and spray drying the resultant mixture. A combination of the two processes described above may be used where a base powder is first produced by wet-mixing and spray drying all or some of the macro-ingredients and then dry blending the remaining ingredients, including carbohydrate, minerals and vitamins and other micronutrients, to create a final formula. Liquid formulae are available in a ready-to-feed format or as a concentrated liquid, which requires dilution, normally 1:1, with water. The manufacturing processes used for these products are similar to those used in the manufacture of recombined milk. If it is desired to produce a liquid formula, the homogenized mixture may be filled into suitable containers, preferably aseptically. However, the liquid composition may also be retorted in the container, suitable apparatus for carrying out the filling and retorting of this nature is commercially available. Methods for supporting motor development The one or more HMOs may be used to promote motor development. The terms “supporting”, “promoting”, “enhancing” or “improving” may be used interchangeably in the context of the present invention. They should be understood as comprising supporting or helping the normal development or growth of an individual. As used herein, “motor development” may refer to a subject’s development in terms of motor skills. Suitable methods and parameters to determine motor development will be known to the skilled person (see e.g. Malina, R.M., 2004. International journal of sport and health science, 2, pp.50-66). Developmental milestones in motor development are described e.g. in Gerber, R.J., et al., 2010. Pediatrics in review, 31(7), pp.267-277. As used herein, “motor skills” may refer to the ability control and coordinate muscles to make desired movements. Motor skills may include fine motor skills and gross motor skills. Fine motor skills require the use of smaller muscle groups (such as those found in wrists, hands, fingers, feet and toes) to perform smaller movements. Gross motor skills require the use of large muscle groups in the legs, torso, and arms to perform tasks such as walking, balancing, and crawling. In some embodiments, the one or more HMOs (e.g. 3’SL) promote the development of fine motor skills. In some embodiments, the one or more HMOs promote the development of gross motor skills. In some embodiments, the one or more HMOs (e.g. LNH and/or DSLNT) promote the development of fine and gross motor skills (i.e. overall motor skills). In some embodiments, the subject’s motor skills are determined by a Bayley scale. The Bayley Scales of Infant and Toddler Development is a standard series of measurements used primarily to assess the development of infants and toddlers, ages 1–42 months. In some embodiments, the subject’s motor skills are determined by Bayley-III, which has three main subtests, including the Motor Scale, which assesses gross and fine motor skills such as grasping, sitting, stacking blocks, and climbing stairs (see e.g. Bayley, N., 2006. Bayley scales of infant and toddler development) As used herein, “supporting motor development” may refer to the support of normal motor development, for example during infancy, childhood and adolescence. Supporting motor development may result in normal motor skills. In one aspect, the present invention provides one or more HMOs for use in supporting motor development in a subject. In another aspect, the present invention provides use of one or more HMOs for supporting motor development in a subject. In another aspect, the present invention provides a method for supporting motor development in a subject, comprising administering to the subject an effective amount of one or more HMOs. In one aspect, the present invention provides 3’-SL for use in supporting motor development (e.g. development of fine motor skills) in a subject. In another aspect, the present invention provides use of 3’-SL for supporting motor development (e.g. development of fine motor skills) in a subject. In another aspect, the present invention provides a method for supporting motor development (e.g. development of fine motor skills) in a subject, comprising administering to the subject an effective amount of 3’-SL. In one aspect, the present invention provides LNH for use in supporting motor development (e.g. development of fine and/or gross motor skills) in a subject. In another aspect, the present invention provides use of LNH for supporting motor development (e.g. development of fine and/or gross motor skills) in a subject. In another aspect, the present invention provides a method for supporting motor development (e.g. development of fine and/or gross motor skills) in a subject, comprising administering to the subject an effective amount of LNH. In one aspect, the present invention provides DSLNT for use in supporting motor development (e.g. development of fine and/or gross motor skills) in a subject. In another aspect, the present invention provides use of DSLNT for supporting motor development (e.g. development of fine and/or gross motor skills) in a subject. In another aspect, the present invention provides a method for supporting motor development (e.g. development of fine and/or gross motor skills) in a subject, comprising administering to the subject an effective amount of DSLNT. Methods for improving motor skills The one or more HMOs may be used to improve motor skills (e.g. fine motor skills and/or gross motor skills). The one or more HMOs according to the present invention may improve motor skills of a subject at 6, 9, 12, 18, 24 or 36 months of age. The one or more HMOs according to the present invention may improve motor skills of a subject aged between 6 to 36 months. The one or more HMOs according to the present invention (e.g.3’SL) may improve motor skills of a subject of 6 months of age. The one or more HMOs according to the present invention (e.g. LNH and/or DSLNT) may improve motor skills of a subject of 12 months of age. Developmental milestones in motor development are described e.g. in Gerber, R.J., et al., 2010. Pediatrics in review, 31(7), pp.267-277. Motor skills of a subject of 6 months of age may include one or more of pivoting in the prone position, crawling in the prone position. Motor skills of a subject of 12 months of age may include one or more of taking a second object while holding on to the first, holding a crayon, scribbling after demonstration, and fine pincer grasp. The one or more HMOs according to the present invention may improve fine motor skills of a subject at 6, 9, 12, 18, 24 or 36 months of age. The one or more HMOs according to the present invention may improve fine motor skills of a subject aged between 6 to 36 months. The one or more HMOs according to the present invention (e.g.3’SL) may improve fine motor skills of a subject of 6 months of age. The one or more HMOs according to the present invention (e.g. LNH and/or DSLNT) may improve fine motor skills of a subject of 12 months of age. The one or more HMOs according to the present invention may improve gross motor skills of a subject at 6, 9, 12, 18, 24 or 36 months of age. The one or more HMOs according to the present invention may improve gross motor skills of a subject aged between 6 to 36 months. The one or more HMOs according to the present invention (e.g. LNH and/or DSLNT) may improve gross motor skills of a subject of 12 months of age. In one aspect, the present invention provides one or more HMOs for use in improving motor skills in a subject. In another aspect, the present invention provides use of one or more HMOs for improving motor skills in a subject. In another aspect, the present invention provides a method for improving motor skills in a subject, comprising administering to the subject an effective amount of one or more HMOs. In one aspect, the present invention provides 3’-SL for use in improving motor skills (e.g. fine motor skills) in a subject. In another aspect, the present invention provides use of 3’-SL for improving motor skills (e.g. fine motor skills) in a subject. In another aspect, the present invention provides a method for improving motor skills (e.g. fine motor skills) in a subject, comprising administering to the subject an effective amount of 3’-SL. In one aspect, the present invention provides LNH for use in improving motor skills (e.g. fine and/or gross motor skills) in a subject. In another aspect, the present invention provides use of LNH for improving motor skills (e.g. fine and/or gross motor skills) in a subject. In another aspect, the present invention provides a method for improving motor skills (e.g. fine and/or gross motor skills) in a subject, comprising administering to the subject an effective amount of LNH. In one aspect, the present invention provides DSLNT for use in improving motor skills (e.g. fine and/or gross motor skills) in a subject. In another aspect, the present invention provides use of DSLNT for improving motor skills (e.g. fine and/or gross motor skills) in a subject. In another aspect, the present invention provides a method for improving motor skills (e.g. fine and/or gross motor skills) in a subject, comprising administering to the subject an effective amount of DSLNT. Subject The subject may be any suitable subject. Suitably, the subject may be a human. In preferred embodiments, the subject is an infant, a toddler, or a young child. The term “infant” may refer to a subject aged from about 0 years to about 1 year. The term “toddler” may refer to a subject aged from about 1 year to about 3 years. The term “young child” may refer to a subject aged from about 3 years to about 10 years, from about 3 years to about 9 years, from about 3 years to about 8 years, from about 3 years to about 7 years, from about 3 years to about 6 years, or from about 3 years to about 5 years. In preferred embodiments, the subject is an infant. In some embodiments, the subject is a newborn infant. In some embodiments, the subject is a preterm infant. In some embodiments, the subject is aged about 5 years or less, about 4 years or less, about 3 years or less, about 2 years or less, or about 1 year or less. In some embodiments, the subject is aged about 12 months or less, about 11 months or less, about 10 months or less, about 9 months or less, about 8 months or less, about 7 months or less, or about 6 months or less. In some embodiments, the subject is aged about 9 months or less. In some embodiments, the one or more HMOs are administered during the first 1, 3, 6, 9, 12, 18, 14, or 36 months of life of a subject. For example, the one or more HMOs are administered to a subject starting from birth up to 12, 18, 24 or 36 months. The subject may be at risk of inadequate motor development. Major risks for poor child development include intrauterine growth restriction, stunting, iodine deficiency, iron-deficiency anemia, malaria, lead exposure, HIV, maternal depression, and inadequate cognitive stimulation. Additionally, maternal education and breastfeeding have been identified as protective factors (Walker, S.P., et al., 2011. The lancet, 378(9799), pp.1325-1338). In some embodiments, the subject has and/or has suffered from intrauterine growth restriction, stunting, iodine deficiency, iron-deficiency anemia, malaria, lead exposure, HIV, maternal depression, and/or inadequate cognitive stimulation. The subject may be at risk of inadequate motor skills. The subject may have suffered from and/or may be suffering from inadequate motor development. Any suitable screening tools may be used (see e.g. Johnson, S. and Marlow, N., 2006. Early human development, 82(3), pp.173-183). The subject may have suffered from and/or may be suffering from inadequate motor skills. This may be determined by any method known in the art, for example using a Bayley scale, such as Bayley-III. EXAMPLES The invention is further described with reference to the following examples. It will be appreciated that the invention as claimed is not intended to be limited in any way by these examples. Example 1 – association of motor capacities with breast milk concentrations of human milk oligosaccharides (HMOs) The inventors investigated the association of motor skills in infants at 6 and 12 months with milk concentrations of specific human milk oligosaccharides (HMOs). Breastmilk HMO levels were tested for breastmilk collected at two and three months from a total cohort of 60 infants. Infant motor skills were scored on the Bayley-III Scales (Bayley N., 2006. Bayley Scales of Infant and Toddler Development, Third Edition. San Antonio, TX: Psychorp) including sub-scores relating to fine and gross motor capacities. A regression model approach was used where the covariates included: maternal net income, SES/education of mothers, weight, gestational age, gender of the infant (covariates were imputed, missing values are replaced by the population mean). Specific HMOs (3’-SL, LNH, and DSLNT) are associated with positive motor skills in infants at 6 and 12 months (see Table 1 below and Figures 1-3). Table 1: Results of regression model approach assessing association between motor skills and HMOs HMOs Bayley’s Motor Scores Infant age P N 3’-SL Increased fine motor scores 12 months 0.007 61 (collected at 2 and 3 months) LNH Increased overall motor scores 6 months 0.003 50 (collected at 3 months) DSLNT Increased overall motor scores 6 months 0.02 55 (collected at 2 months) The inventor’s findings surprisingly show an association of the specified HMOs with positive motor skills in infants at 6 and 12 months. The inventors surprisingly show that 3’-SL in breast milk at 2 and 3 months is associated with positive fine motor skills at 12 months, and LNH in breast milk at 3 months and DSLNT in breast milk at 2 months are individually associated with overall motor scores at 6 months. An improvement in motor skills is particularly beneficial in a subject aged 6 months, as this is a pivotal age for key milestones for overall motor skills (see e.g. Scharf R.J., Scharf G.J., Stroustrup A., 2016. Pediatr Rev. 37(1), pp25-37) including pivoting in the prone position, crawling in the prone position, and taking a second object while holding on to the first. 12 months is also pivotal age for key milestones for fine motor skills including holding a crayon, scribbling after demonstration, and fine pincer grasp. EMBODIMENTS Various preferred features and embodiments of the present invention will now be described with reference to the following numbered paragraphs (paras). 1. One or more human milk oligosaccharides (HMOs) for use in supporting motor development in a subject, wherein the one or more HMOs comprise or consist of: 3’ sialyllactose (3’-SL), lacto-N-hexaose (LNH), and/or disyallacto-N-tetraose (DSLNT). 2. Use of one or more human milk oligosaccharides (HMOs) for supporting motor development in a subject, wherein the one or more HMOs comprise or consist of: 3’ sialyllactose (3’-SL), lacto-N-hexaose (LNH), and/or disyallacto-N-tetraose (DSLNT). 3. A method for supporting motor development in a subject, comprising administering to the subject an effective amount of one or more human milk oligosaccharides (HMOs), wherein the one or more HMOs comprise or consist of: 3’ sialyllactose (3’-SL), lacto-N-hexaose (LNH), and/or disyallacto-N-tetraose (DSLNT). 4. The one or more HMOs for use according to para 1, the use according to para 2, or the method according to para 3, wherein the one or more HMOs comprise or consist of 3’-SL. 5. The one or more HMOs for use according to para 1 or 4, the use according to para 2 or 4, or the method according to para 3 or 4, wherein the one or more HMOs comprise or consist of LNH. 6. The one or more HMOs for use according to any of paras 1 or 4-5, the use according to any of paras 2 or 4-5, or the method according to any of paras 3 or 4-5, wherein the one or more HMOs comprise or consist of DSLNT. 7. The one or more HMOs for use according to any of paras 1 or 4-6, the use according to any of paras 2 or 4-6, or the method according to any of paras 3 or 4-6, wherein the one or more HMOs are administered by oral administration. 8. The one or more HMOs for use according to any of paras 1 or 4-7, the use according to any of paras 2 or 4-7, or the method according to any of paras 3 or 4-7, wherein the one or more HMOs are administered separately, simultaneously or sequentially, preferably wherein the one or more HMOs are administered simultaneously. 9. The one or more HMOs for use according to any of paras 1 or 4-8, the use according to any of paras 2 or 4-8, or the method according to any of paras 3 or 4-8, wherein the one or more HMOs are administered to the subject in a total amount of from about 0.05 g/day to about 5 g/day. 10. The one or more HMOs for use according to any of paras 1 or 4-9, the use according to any of paras 2 or 4-9, or the method according to any of paras 3 or 4-9, wherein 3’-SL is administered to the subject in an amount of from about 0.05 g/day to about 5 g/day. 11. The one or more HMOs for use according to any of paras 1 or 4-10, the use according to any of paras 2 or 4-10, or the method according to any of paras 3 or 4-10, wherein LNH is administered to the subject in an amount of from about 0.05 g/day to about 5 g/day. 12. The one or more HMOs for use according to any of paras 1 or 4-11, the use according to any of paras 2 or 4-11, or the method according to any of paras 3 or 4-11, wherein DSLNT is administered to the subject in an amount of from about 0.1 g/day to about 5 g/day. 13. The one or more HMOs for use according to any of paras 1 or 4-12, the use according to any of paras 2 or 4-12, or the method according to any of paras 3 or 4-12, wherein the one or more HMOs are in the form of a nutritional composition. 14. The one or more HMOs for use according to para 13, the use according to para 13, or the method according to para 13, wherein the nutritional composition is an infant formula, a follow- on formula, or a growing-up milk, preferably wherein the nutritional composition is an infant formula. 15. The one or more HMOs for use according to para 13 or 14, the use according to para 13 or 14, or the method according to para 13 or 14, wherein the nutritional composition comprises the one or more HMOs in a total amount of from about 0.05 g/L to about 5 g/L. 16. The one or more HMOs for use according to any of paras 12-15, the use according to any of paras 12-15, or the method according to any of paras 12-15, wherein the nutritional composition comprises 3’-SL in an amount of from about 0.05 g/L to about 1.0 g/L. 17. The one or more HMOs for use according to any of paras 12-16, the use according to any of paras 12-16, or the method according to any of paras 12-16, wherein the nutritional composition comprises LNH in an amount of from about 0.05 g/L to about 1.0 g/L. 18. The one or more HMOs for use according to any of paras 12-17, the use according to any of paras 12-17, or the method according to any of paras 12-17, wherein the nutritional composition comprises DSLNT in an amount of from about 0.1 g/L to about 2.0 g/L. 19. The one or more HMOs for use according to any of paras 1 or 4-18, the use according to any of paras 2 or 4-18, or the method according to any of paras 3 or 4-18, wherein the subject is a human subject. 20. The one or more HMOs for use according to any of paras 1 or 4-19, the use according to any of paras 2 or 4-19, or the method according to any of paras 3 or 4-19, wherein the subject is an infant, a toddler or a young child. 21. The one or more HMOs for use according to any of paras 1 or 4-20, the use according to any of paras 2 or 4-20, or the method according to any of paras 3 or 4-20, wherein the subject is an infant. 22. The one or more HMOs for use according to any of paras 1 or 4-21, the use according to any of paras 2 or 4-21, or the method according to any of paras 3 or 4-21, wherein the subject is aged about 12 months or younger. 23. The one or more HMOs for use according to any of paras 1 or 4-22, the use according to any of paras 2 or 4-22, or the method according to any of paras 3 or 4-22, wherein the subject is aged about 11 months or younger, about 10 months or younger, about 9 months or younger, about 8 months or younger, about 7 months or younger, or about 6 months or younger. 24. The one or more HMOs for use according to any of paras 1 or 4-23, the use according to any of paras 1 or 4-23, or the method according to any of paras 1 or 4-23, wherein the one or more HMOs promotes the development of the subject’s fine motor skills and/or gross motor skills. 25. The one or more HMOs for use according to any of paras 1 or 4-24, the use according to any of paras 2 or 4-24, or the method according to any of paras 3 or 4-24, wherein the one or more HMOs improve the subject’s motor skills. 26. The one or more HMOs for use according to any of paras 1 or 4-25, the use according to any of paras 2 or 4-25, or the method according to any of paras 3 or 4-25, wherein the one or more HMOs improve the ability of the subject to control and coordinate muscles to make desired movements. 27. The one or more HMOs for use according to any of paras 1 or 4-26, the use according to any of paras 2 or 4-26, or the method according to any of paras 3 or 4-26, wherein the subject’s motor skills are determined using a Bayley scale, such as Bayley-III. Although the invention has been described by way of example, it should be appreciated that variations and modifications may be made without departing from the scope of the invention as defined in the claims. Furthermore, where known equivalents exist to specific features, such equivalents are incorporated as if specifically referred in this specification.

Claims

CLAIMS 1. One or more human milk oligosaccharides (HMOs) for use in supporting motor development in a subject, wherein the one or more HMOs comprise or consist of: 3’ sialyllactose (3’-SL), lacto-N-hexaose (LNH), and/or disyallacto-N-tetraose (DSLNT). 2. The one or more HMOs for use according to claim 1, wherein the one or more HMOs comprise or consist of 3’-SL. 3. The one or more HMOs for use according to claim 1 or 2, wherein the one or more HMOs comprise or consist of LNH. 4. The one or more HMOs for use according to any preceding claim, wherein the one or more HMOs comprise or consist of DSLNT. 5. The one or more HMOs for use according to any preceding claim, wherein the one or more HMOs are administered by oral administration. 6. The one or more HMOs for use according to any preceding claim, wherein the one or more HMOs are administered separately, simultaneously or sequentially, preferably wherein the one or more HMOs are administered simultaneously. 7. The one or more HMOs for use according to any preceding claim, wherein the one or more HMOs are administered to the subject in a total amount of from about 0.05 g/day to about 5 g/day. 8. The one or more HMOs for use according to any preceding claim, wherein the one or more HMOs are in the form of a nutritional composition. 9. The one or more HMOs for use according to claim 8, wherein the nutritional composition is an infant formula, a follow-on formula, or a growing-up milk, preferably wherein the nutritional composition is an infant formula. 10. The one or more HMOs for use according to claim 8 or 9, wherein the nutritional composition comprises the one or more HMOs in a total amount of from about 0.05 g/L to about 5 g/L. 11. The one or more HMOs for use according to any preceding claim, wherein the subject is an infant, a toddler or a young child, preferably wherein the subject is an infant. 12. The one or more HMOs for use according to any preceding claim, wherein the subject is aged about 12 months or younger, about 11 months or younger, about 10 months or younger, about 9 months or younger, about 8 months or younger, about 7 months or younger, or about 6 months or younger. 13. The one or more HMOs for use according to any preceding claim, wherein the one or more HMOs promotes the development of the subject’s fine motor skills and/or gross motor skills. 14. The one or more HMOs for use according to any preceding claim, wherein the one or more HMOs improve the ability of the subject to control and coordinate muscles to make desired movements. 15. The one or more HMOs for use according to any preceding claim, wherein the subject’s motor skills are determined using a Bayley scale, such as Bayley-III.